Bioprocessing Thermo Fisher Scientific Sets Up 160-Million-Dollar Biomanufacturing Unit in USA
The mega biomanufacturing facility will cater to the growing demand for biologic materials and is part of the company’s 650-million-dollar multi-year investment strategy which aims to expand its bioprocessing production capabilities.
Waltham/USA – Thermo Fisher Scientific recently inaugurated a new biomanufacturing facility in Chelmsford, Massachusetts, USA. The 160 million dollar, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s 650-million-dollar multi-year investment to expand its bioprocessing production capabilities.
The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster. With the opening of the site in Chelmsford, Thermo Fisher continues to bring its capacity investments online to support customers as they grow and scale.
Jean Luo, vice president and general manager, purification and pharma analytics, Thermo Fisher Scientific said, “The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market. This ultimately helps ensure more patients get the treatments they need faster.”
When fully staffed, the Chelmsford site will employ up to 250 people in roles across manufacturing, engineering, procurement, quality, warehousing, site leadership and more. This site is part of Thermo Fisher’s global bioprocessing supply network that spans across 100 countries and helps ensure critical medicines reach patients.